NCI R50 Clinician Scientist Award

摘要/总结 NCI临床试验网络对于通过加速发现来加强国家的癌症护理至关重要 新型癌症治疗方法和治疗策略。这项工作的核心是临床科学家，他们 开发、实施、管理和监督这些个体试验和试验网络。而 重要的是，这些临床医生经常承担重要的临床，行政和教学任务 可能抑制对NCI申办的临床试验活动做出实质性贡献的职责。R50 研究专家/临床科学家奖旨在保护时间，并允许临床科学家 通过在以下领域的领导地位，为NCI申办的临床试验和NCI临床试验网络做出重大贡献 开展国家临床试验，在其机构中实施NCI临床试验， 为NCI临床试验网络提供服务。 博士布赖恩乔纳斯，医学博士，博士，是白血病专家和副教授在系 UC Davis Comprehensive Cancer Center（UCDCCC）血液学/肿瘤学作为一个活跃而高度 他是加州大学戴维斯分校的一位敬业的临床科学家和试验者，他已经确立了自己作为开放临床研究领域的领导者的地位。 用于治疗AML、MDS、急性淋巴细胞白血病（ALL）和其他血液恶性肿瘤的试验。 此外，他还在癌症临床试验部门获得了令人垂涎的“顶级累积者”奖。他的临床 他的研究得到了他的转化研究的补充，涉及AML生物标志物，化学敏感性和 白血病干细胞的治疗靶向。作为UCDCCC的资产，他曾在几个临床项目中担任PI 作为临床试验管理的领导者。这包括主持UCDCCC血液学 肿瘤疾病小组委员会和UCDCCC数据和安全性监测委员会。 除了在加州大学戴维斯分校的贡献外，乔纳斯博士还为多学科临床和翻译做出了贡献。 白血病委员会和西南肿瘤组工作组（SWOG）等团队，以及 加州癌症联盟在UCDCCC，国家临床试验中心， 试验网络（NCTN）和实验治疗药物临床试验网络（ET-CTN）。这包括他的 担任通过CTEP项目小组机制和 通过NCTN开发的ECOG-ACRIN AML试验的SWOG冠军。他也是一个活跃的 UM1联盟、加州癌症联盟（CCC）的参与者，以及CCC Heme的成员 工作组。总体而言，Jonas博士是NCI R50研究的合格临床科学家候选人 专家奖，并在国家临床发展方面表现出先前和持续的领导地位。 试验，在ucd实施nci申办的临床试验，并通过为nci临床试验网络提供服务 加入我们的CCC R50奖将促进他的研究计划的持续发展， 加强其机构和国家领导能力。

ABSTRACT/SUMMARY NCI clinical trials networks are essential to strengthen the cancer care of the nation by expediting the discovery of novel cancer treatments and therapeutic strategies. Central to this effort are the clinician scientists who development, implement, manage, and provide oversight to these individual trials and trial networks. While essential, these clinicians are frequently tasked with significant clinical, administrative, and teaching responsibilities that may inhibit substantiative contribution to NCI-sponsored clinical trial activity. The R50 Research Specialist /Clinician Scientist Award is designed to protect time and allow the clinician scientist to significantly contribute to NCI-sponsored clinical trials and NCI clinical trials networks through leadership in the development of national clinical trials, implementation of NCI clinical trials in their institutions, and national service to the NCI clinical trials networks. Dr. Brian Jonas, MD, PhD, is a leukemia specialist and an Associate Professor within the Department of Hematology/Oncology at UC Davis Comprehensive Cancer Center (UCDCCC). As an active and highly dedicated clinical scientist and trialist at UC Davis, he has established himself as a leader in opening clinical trials for the treatment of AML, MDS, acute lymphoblastic leukemia (ALL) and other hematologic malignancies. Moreover, he has received the coveted “Top Accrurer” Award within the cancer clinical trials unit. His clinical research is complemented by his translational studies involving AML biomarkers, chemosensitivity and therapeutic targeting of leukemia stem cells. As an asset to UCDCCC, he has served as PI on several clinical trials and as a leader in clinical trials management. This includes chairing the UCDCCC Hematologic Malignancies Disease Team Committee and the UCDCCC Data and Safety Monitoring Committee. In addition to his contributions at UC Davis, Dr. Jonas has contributed to multidisciplinary clinical and translational teams such as the Leukemia Committee and Working Group for the Southwest Oncology Group (SWOG), and the Calif ornia Cancer Consortium to shape and inf orm clinical trial portf olios at the UCDCCC, the National Clinical Trials Network (NCTN) and the Experimental Therapeutics Clinical Trials Network (ET-CTN). This includes his service as national chair of two ECTCN trials developed through the CTEP Project Team mechanism and the SWOG champion for an ECOG-ACRIN AML trial in development through the NCTN. He is also an active participant in the UM1 Consortium, the California Cancer Consortium (CCC), and a member of the CCC Heme Working Group. Overall, Dr. Jonas is a well-qualified clinician scientist candidate for the NCI R50 Research Specialist Award and has demonstrated prior and continuing leadership in the development of national clinical trials, implementation of NCI-sponsored clinical trials at UCD, and service to NCI clinical trial networks through participation in our CCC. The R50 award will facilitate continued growth of his research program and advancement of his institutional and national leadership.